Changchun High-tech: Subsidiary GS3-007a dry blend suspension domestic drug production registration clinical trial application accepted.

Changchun High-Tech Announcement: Recently, the holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the "Acceptance Notice" issued by the National Medical Products Administration for the domestic production drug registration clinical trial application of Jinsai Pharmaceutical GS3-007a dry powder suspension. GS3-007a dry powder suspension is a orally administered small molecule growth hormone secretion promoter independently developed by Jinsai Pharmaceutical, classified as Class 1 chemical drugs, intended for the treatment of idiopathic short stature.